Abstract
Anticoagulant therapy is effective at preventing the development of venous thromboembolism in high-risk patients, and reduces morbidity and mortality in individuals with established thromboembolic disease. Vitamin K antagonists and heparins are currently the most commonly used anticoagulant drugs, but they have practical limitations. Therefore, new antithrombotic agents with predictable dose-responses (thereby decreasing the need for monitoring without compromising efficacy or safety), ideally available in an oral formulation and with a rapidly reversible anticoagulant effect, are needed. New drugs fulfilling some of the above criteria have been developed and have proven to be effective agents for the treatment and prevention of venous thromboembolism.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Anticoagulants / pharmacology
-
Anticoagulants / therapeutic use*
-
Azetidines / therapeutic use
-
Benzylamines / therapeutic use
-
Blood Coagulation / drug effects
-
Factor VII / antagonists & inhibitors
-
Factor Xa Inhibitors
-
Fondaparinux
-
Helminth Proteins / therapeutic use
-
Humans
-
Oligosaccharides / therapeutic use
-
Polysaccharides / therapeutic use
-
Recombinant Proteins
-
Thrombin / antagonists & inhibitors
-
Thromboembolism / drug therapy*
-
Thromboembolism / prevention & control*
-
Thrombomodulin
-
Thromboplastin / antagonists & inhibitors
-
Treatment Outcome
-
Venous Thrombosis / drug therapy*
-
Venous Thrombosis / prevention & control*
Substances
-
ART123
-
Anticoagulants
-
Azetidines
-
Benzylamines
-
Factor Xa Inhibitors
-
Helminth Proteins
-
Oligosaccharides
-
Polysaccharides
-
Recombinant Proteins
-
Thrombomodulin
-
anti-coagulant protein C2, Ancylostoma caninum
-
ximelagatran
-
idraparinux
-
Factor VII
-
Thromboplastin
-
Thrombin
-
Fondaparinux